Orthocell Posts $3.2M Quarter Revenue, $300K U.S. Remplir Sales
Orthocell reported March quarter revenue of $3.2 million and YTD sales of $9.4 million, up 45% year-on-year, supported by $300,000 in U.S. Remplir sales, including $170,000 in March. The company holds $48 million in cash and deposits and has secured approvals at 32 U.S. hospitals while expanding Remplir access across 16 states.
1. March Quarter Sales and Year-to-Date Growth
Orthocell generated A$3.2 million in revenue during the March quarter, matching the prior period, and achieved A$9.4 million in sales over the first nine months of FY26, a 45% increase on the prior corresponding period.
2. U.S. Remplir Commercial Rollout
U.S. revenue for the nerve repair product Remplir reached A$300,000 in the quarter, with A$170,000 booked in March, while the distributor network now spans 16 states covering 40% of the population and unit sales totalled 115.
3. Robust Balance Sheet Position
At 31 March 2026, Orthocell held A$7.8 million in cash and A$40.2 million in term deposits, bolstered by a A$3 million R&D tax incentive refund, underpinning its commercial expansion plans.
4. Department of Defence Approval and Outlook
Subsequent to quarter end, Orthocell secured approval for Remplir use across 221 U.S. Department of Defence medical centres and completed the first surgical case, marking a strategic inflection point for further surgeon engagement and market penetration.